A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's.
Tornling G, Edenius C, Pauling JD, Denton CP, Olsson A, Kowalski J, Murray A, Anderson M, Bhat S, Del Galdo F, Hall F, Korkosz M, Krasowska D, Olas J, Smith V, van Laar JM, Vonk MC, Wojteczek A, Herrick AL.
Tornling G, et al. Among authors: kowalski j.
Rheumatology (Oxford). 2024 Jan 30:keae049. doi: 10.1093/rheumatology/keae049. Online ahead of print.
Rheumatology (Oxford). 2024.
PMID: 38291895